Modified DNA backbone enables success of existing and novel oligonucleotide therapeutics
In the article describes how the chemical and biochemical properties of this significant nucleic acid modification have made DNA suitable for use as therapeutic agents. Initial applications focused on cleaving the mRNA product of genes to block protein production. Dr. Eckstein explores novel applications including microRNA and long non-coding RNA targets and the use of decoy oligonucleotides.
"We will advance the field of nucleic acid therapeutics by looking to key opinion leaders to educate and initiate the experienced and newcomers alike. In this review, Dr. Eckstein has produced a tour de force concerning the therapeutic application of phosphorothioates," says Executive Editor Graham C. Parker, PhD, The Carman and Ann Adams Department of Pediatrics, Wayne State University School of Medicine, Children's Hospital of Michigan, Detroit, MI.
Original publication
Fritz Eckstein et al.; "Phosphorothioates, Essential Components of Therapeutic Oligonucleotides.";Nucleic Acid Therapeutics 2014.
Original publication
Fritz Eckstein et al.; "Phosphorothioates, Essential Components of Therapeutic Oligonucleotides.";Nucleic Acid Therapeutics 2014.
Organizations
Other news from the department science
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.